治疗癌症相关血栓的临床挑战:以临床为导向的审查
Idan Goldberg1,2,3, Galia Spectre1,2, Pia Raanani1,2
1Institute of Hematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel.
Acta haematologica
|December 11, 2024
概括
管理与癌症相关的血栓形成 (CAT) 需要仔细考虑患者的因素. 本综述探讨了在复杂的CAT病例中使用直接口服抗凝剂 (DOAC) 的挑战和策略.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症相关血栓瘤 (CAT) 存在独特的管理挑战,包括出血风险和药物相互作用.
- 低分子量肝素 (LMWH) 在历史上是标准的,但现在有直接口服抗凝剂 (DOAC).
- 患者异质性需要量身定制的抗凝剂策略,以获得最佳的CAT结果.
研究的目的:
- 审查有关在特定临床场景中管理CAT的当前文献.
- 在复杂的CAT病例中提出基于证据的临床方法来选择抗凝剂.
- 为了应对包括脑转移,胃肠道恶性瘤,药物相互作用和血小板衰竭在内的挑战.
主要方法:
- 对癌症患者血栓形成管理的当前文献的综述.
- 分析了四种不同的理论临床病例情景.
- 讨论各种CAT环境中的抗凝剂选择,包括LMWH和DOAC.
主要成果:
- 大脑转移和CAT:用抗凝剂平衡内出血风险至关重要;LMWH和DOAC都是可选的.
- 胃肠道恶性瘤:有冲突的出血风险数据;对于晚期,无法切除的疾病,可能更喜欢使用LMWH.
- 药物相互作用 (DDI):由于潜在的代谢或出血风险变化,有限的数据需要谨慎使用DOAC.
- 血栓细胞减小:管理取决于血栓事件的严重程度和时间.
结论:
- 在CAT中选择抗凝剂需要根据临床背景和患者特定因素进行个性化评估.
- DOACs为LMWH提供了替代方案,但必须仔细考虑DDI和血小板缺血等特定挑战.
- 需要进一步的研究来澄清在复杂的子组中管理CAT的最佳策略.
相关概念视频
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:27Tumor Immunotherapy
476
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
01:24Disorders of Hemostasis
707
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
707